These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17902495)

  • 1. Researching safety and cost-effectiveness in the life cycle of nanomedicine.
    Faunce T; Shats K
    J Law Med; 2007 Aug; 15(1):128-35. PubMed ID: 17902495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policy challenges of nanomedicine for Australia's PBS.
    Faunce TA
    Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in Australia.
    Faunce TA
    Med J Aust; 2007 Feb; 186(4):189-91. PubMed ID: 17309421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of nanomedicine: estimating the real size of nano-costs.
    Bosetti R; Jones SL
    Nanomedicine (Lond); 2019 Jun; 14(11):1367-1370. PubMed ID: 31169449
    [No Abstract]   [Full Text] [Related]  

  • 5. Is New Zealand's regulation of nanomedical products adequate?
    Moore J
    J Law Med; 2011 Sep; 19(1):112-27. PubMed ID: 21988014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?
    Bosetti R
    Nanomedicine (Lond); 2015 Jul; 10(12):1851-3. PubMed ID: 26139120
    [No Abstract]   [Full Text] [Related]  

  • 7. Nanomedicine: An unresolved regulatory issue.
    Chan VS
    Regul Toxicol Pharmacol; 2006 Dec; 46(3):218-24. PubMed ID: 17081666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking temperature--a review of European Union regulation in nanomedicine.
    D'Silva J; van Calster G
    Eur J Health Law; 2009 Sep; 16(3):249-69. PubMed ID: 19788003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
    Nijhara R; Balakrishnan K
    Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
    Mackler BF; Barach M
    J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine: real commercial potential or just hype?
    Webster TJ
    Int J Nanomedicine; 2006; 1(4):373-4. PubMed ID: 17722271
    [No Abstract]   [Full Text] [Related]  

  • 12. Exploring emerging nanobiotechnology drugs and medical devices.
    Paradise J; Diliberto GM; Tisdale AW; Kokkoli E
    Food Drug Law J; 2008; 63(2):407-20. PubMed ID: 18561467
    [No Abstract]   [Full Text] [Related]  

  • 13. Globalization of biotechnology and the public health challenges accompanying it.
    Malinowski MJ
    Albany Law Rev; 1996; 60(1):119-69. PubMed ID: 10170488
    [No Abstract]   [Full Text] [Related]  

  • 14. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EU wrangles internally over safety of donated tissues and cells.
    Vermij P
    Nat Biotechnol; 2003 Dec; 21(12):1420. PubMed ID: 14647315
    [No Abstract]   [Full Text] [Related]  

  • 16. Will the nanomedicine "patent land grab" thwart commercialization?
    Bawa R
    Nanomedicine; 2005 Dec; 1(4):346-50. PubMed ID: 17292108
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond an uninformed public? A comparative analysis of survey data concerning patenting and commodification.
    Outerbridge T
    Health Law Rev; 2003; 11(2):3-7. PubMed ID: 15706696
    [No Abstract]   [Full Text] [Related]  

  • 18. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Britain opens biotech regulation to greater public involvement.
    Masood E
    Nature; 1999 May; 399(6734):287-8. PubMed ID: 10360555
    [No Abstract]   [Full Text] [Related]  

  • 20. Law and ethics for the bioeconomy and beyond.
    Bennett B
    J Law Med; 2007 Aug; 15(1):7-13. PubMed ID: 17902484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.